Cargando…

Design of FLAIR: a Phase 2b Study of the 5-Lipoxygenase Activating Protein Inhibitor AZD5718 in Patients With Proteinuric CKD

INTRODUCTION: Patients with chronic kidney disease (CKD) remain at risk for kidney and cardiovascular events resulting from residual albuminuria, despite available treatments. Leukotrienes are proinflammatory and vasoconstrictive lipid mediators implicated in the etiology of chronic inflammatory dis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Heerspink, Hiddo J.L., Law, Gordon, Psachoulia, Konstantina, Connolly, Kathleen, Whatling, Carl, Ericsson, Hans, Knöchel, Jane, Lindstedt, Eva-Lotte, MacPhee, Iain
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8589691/ https://www.ncbi.nlm.nih.gov/pubmed/34805632 http://dx.doi.org/10.1016/j.ekir.2021.08.018

Ejemplares similares

Pharmacokinetics, Pharmacodynamics, and Tolerability of AZD5718, an Oral 5-Lipoxygenase-Activating Protein (FLAP) Inhibitor, in Healthy Japanese Male Subjects
por: Knöchel, Jane, et al.
Publicado: (2021)

Initial Clinical Experience with AZD5718, a Novel Once Daily Oral 5‐Lipoxygenase Activating Protein Inhibitor
por: Ericsson, Hans, et al.
Publicado: (2018)

Phase 1 Pharmacokinetic Study of AZD5718 in Healthy Volunteers: Effects of Coadministration With Rosuvastatin, Formulation and Food on Oral Bioavailability
por: Ericsson, Hans, et al.
Publicado: (2019)

Design and rationale of FLAVOUR: A phase IIa efficacy study of the 5-lipoxygenase activating protein antagonist AZD5718 in patients with recent myocardial infarction
por: Prescott, Eva, et al.
Publicado: (2020)

Safety, tolerability, pharmacokinetics and effect on serum uric acid of the myeloperoxidase inhibitor AZD4831 in a randomized, placebo‐controlled, phase I study in healthy volunteers
por: Gan, Li‐Ming, et al.
Publicado: (2019)

Early Clinical Experience With AZD4831, A Novel Myeloperoxidase Inhibitor, Developed for Patients With Heart Failure With Preserved Ejection Fraction
por: Nelander, Karin, et al.
Publicado: (2021)

Non-Proteinuric Diabetic Nephropathy
por: Robles, Nicolas Roberto, et al.
Publicado: (2015)

Lipoprotein Modulation of Proteinuric Renal Injury
por: Tsuchida, Yohei, et al.
Publicado: (2019)

TRPC Channels in Proteinuric Kidney Diseases
por: Hall, Gentzon, et al.
Publicado: (2019)

Targeting tubulointerstitial remodeling in proteinuric nephropathy in rats
por: Yazdani, Saleh, et al.
Publicado: (2015)

Progress and opportunities in measuring the burden of Chronic Kidney Disease
por: Vart, Priya, et al.
Publicado: (2022)

Solar flair.
por: Manuel, John S
Publicado: (2003)

Anti-Proteinuric Effect of Sulodexide in Immunoglobulin A Nephropathy
por: Bang, Kitae, et al.
Publicado: (2011)

Haematuria Increases Progression of Advanced Proteinuric Kidney Disease
por: Yuste, Claudia, et al.
Publicado: (2015)

Clinicopathologic and pathologic characteristics of feline proteinuric kidney disease
por: Rayhel, Laura H, et al.
Publicado: (2020)

Dicarbonyl-modified lipoproteins contribute to proteinuric kidney injury
por: Zhong, Jianyong, et al.
Publicado: (2022)

Discovery of AZD4831, a Mechanism-Based Irreversible Inhibitor of Myeloperoxidase, As a Potential Treatment for Heart Failure with Preserved Ejection Fraction
por: Inghardt, Tord, et al.
Publicado: (2022)

Correction to “Discovery of AZD4831, a Mechanism-Based Irreversible Inhibitor of Myeloperoxidase, As a Potential Treatment for Heart Failure with Preserved Ejection Fraction”
por: Inghardt, Tord, et al.
Publicado: (2022)

Non-Immunologic Actions of Calcineurin Inhibitors in Proteinuric Kidney Diseases
por: Spurney, Robert Frank
Publicado: (2014)

Proximal Tubular Expression Patterns of Megalin and Cubilin in Proteinuric Nephropathies
por: Sun, Jia, et al.
Publicado: (2017)

Epidemiology of low-proteinuric chronic kidney disease in renal clinics
por: De Nicola, Luca, et al.
Publicado: (2017)

Exposure–response relationships of dapagliflozin on cardiorenal risk markers and adverse events: A pooled analysis of 13 phase II/III trials
por: Koomen, Jeroen V., et al.
Publicado: (2020)

Efficacy of Dapagliflozin by Baseline Diabetes Medications: A Prespecified Analysis From the DAPA-CKD Study
por: Beernink, Jelle M., et al.
Publicado: (2023)

Intramuscular AZD7442 (Tixagevimab–Cilgavimab) for Prevention of Covid-19
por: Levin, Myron J., et al.
Publicado: (2022)

Efficacy and Safety of Dapagliflozin in Patients With CKD Across Major Geographic Regions
por: Vart, Priya, et al.
Publicado: (2022)

Treating Early-Stage CKD With New Medication Therapies: Results of a CKD Patient Survey Informing the 2020 NKF-FDA Scientific Workshop on Clinical Trial Considerations for Developing Treatments for Early Stages of Common, Chronic Kidney Diseases
por: Damron, Kelli Collins, et al.
Publicado: (2022)

Racial/Ethnic Differences in the Prevalence of Proteinuric and Nonproteinuric Diabetic Kidney Disease
por: Bhalla, Vivek, et al.
Publicado: (2013)

Proteinuric kidney disease in children at Queen Elizabeth Central Hospital, Malawi
por: Mwanza, Zondiwe Victor, et al.
Publicado: (2018)

Proteinuric Kidney Diseases: A Podocyte's Slit Diaphragm and Cytoskeleton Approach
por: Yu, Samuel Mon-Wei, et al.
Publicado: (2018)

Maternal Venous Hemodynamic Dysfunction in Proteinuric Gestational Hypertension: Evidence and Implications
por: Gyselaers, Wilfried
Publicado: (2019)

Steroid-Associated Side Effects in Patients With Primary Proteinuric Kidney Disease
por: Oh, Gia J., et al.
Publicado: (2019)

Immunohistochemical Expression of FOXP3+ Regulatory T Cells in Proteinuric Primary Glomerulopathies
por: Vlachopanos, Georgios, et al.
Publicado: (2021)

Prediction of Chronic Kidney Disease Stage 3 by CKD273, a Urinary Proteomic Biomarker
por: Pontillo, Claudia, et al.
Publicado: (2017)

Multimarker Panels in Diabetic Kidney Disease: The Way to Improved Clinical Trial Design and Clinical Practice?
por: Perco, Paul, et al.
Publicado: (2018)

Efficacy and Safety of Dapagliflozin by Baseline Glycemic Status: A Prespecified Analysis From the DAPA-CKD Trial
por: Persson, Frederik, et al.
Publicado: (2021)

Comparison between 3D SPACE FLAIR and 3D TSE FLAIR in Menière’s disease
por: Bernaerts, Anja, et al.
Publicado: (2022)

The Kidney Protective Effects of the Sodium–Glucose Cotransporter-2 Inhibitor, Dapagliflozin, Are Present in Patients With CKD Treated With Mineralocorticoid Receptor Antagonists
por: Provenzano, Michele, et al.
Publicado: (2021)

Arterial stiffness and renal impairment in non‐proteinuric type 2 diabetic patients
por: Nakao, Keiko, et al.
Publicado: (2011)

Thrombospondin 1 Deficiency Ameliorates the Development of Adriamycin-Induced Proteinuric Kidney Disease
por: Maimaitiyiming, Hasiyeti, et al.
Publicado: (2016)

A previously unrecognized role of C3a in proteinuric progressive nephropathy
por: Morigi, Marina, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_0c7v1lqngneskol911cqg77k6l